Evidence map›Paper›PMID 37652232›Full record

ReviewAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology2024

Future of biologics in pediatric asthma: Optimizing response, early introduction, and equitable access to treatment.

Ianthe R M Schepel, Tina M Banzon, Wanda Phipatanakul

Open access · bronzeAbstract readReview
In one paragraph

Review in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Prognostic utility of pre-biologic treatment correlates of childhood severe asthma exacerbation risk: Real world evidence.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025
    Article
  5. Asthma Phenotypes and Biomarkers.Respiratory care · 2025
    Review
  6. Article
  7. Current Challenges in Pediatric Asthma.Children (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ianthe R M SchepelDepartment of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Tina M BanzonDivision of Allergy and Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Wanda PhipatanakulDivision of Allergy and Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: Wanda.Phipatanakul@childrens.harvard.edu.
Boston Children's Hospital · US

Funding

Controlling and preventing Asthma progression and Severity in Kids (CASK)U01AI126614 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI PHIPATANAKUL, WANDA · 2016 to 2023
$21.0M
Controlling and Preventing Asthma Progression and Severity in Kids with Omalizumab Extension (PARK-EXT)U01AI179563 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI WANDA PHIPATANAKUL · 2024 to 2026
$6.8M
Environmental Risk Factors for Pediatric Sleep Disordered BreathingR01HL137192 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI PHIPATANAKUL, WANDA · 2017 to 2020
$3.5M
Novel NOTCH4 Pathway of Asthma Severity in Urban School Children: Clinical Research Center, Boston Children’s HospitalU01AI160087 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI Talal Amine Chatila, WANDA PHIPATANAKUL · 2021 to 2026
$2.8M
Midcareer Investigator Award: Urban School Allergen Exposures and Childhood AsthmK24AI106822 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI PHIPATANAKUL, WANDA · 2013 to 2022
$1.9M
Evaluation of radon progeny and air pollution effects in asthmaK23ES035459 · NIEHS · BOSTON CHILDREN'S HOSPITAL · PI Tina Banzon · 2023 to 2026
$830k
NHLBI NIH HHS R01 HL137192NIAID NIH HHS K24 AI106822NIAID NIH HHS U01 AI126614NIAID NIH HHS U01 AI160087NIAID NIH HHS U01 AI179563NIEHS NIH HHS K23 ES035459
6 · The paper itself

Abstract

objectiveTo evaluate the current evidence, its limitations, and future research directions for the use of biologics in pediatric asthma, with a particular focus on the potential use of biologics to prevent pediatric asthma and equity issues in access to biologic treatment and research participation. DATA SOURCES: PubMed articles about the use of biologics in pediatric asthma were searched up to May 2023. STUDY SELECTIONS: Recent (2019-2023) original research articles and reviews were prioritized.

resultsAlthough there are now 5 U.S. Food and Drug Administration-approved biologics for use in pediatric asthma, there are important knowledge gaps that ongoing research seeks to address, which include (1) the long-term efficacy and safety of using biologics in children, (2) the comparative efficacy of different biologics, (3) multi-omics-based classification of asthma endotypes and phenotypes in children to find potential new therapeutic targets and enable identification and validation of new biomarkers that may predict and help monitor response to treatment, and (4) whether starting biologics in early childhood can modify the natural history of asthma and potentially prevent asthma development. SUMMARY: To promote equitable access to biologics and optimize asthma outcomes, future research should recruit patients across the full spectrum of socioeconomic and racial/ethnic backgrounds. Large-scale national and international collaborations between asthma researchers and clinicians are also necessary to fully understand the role of biologics in pediatric asthma.

Indexed as

Anti-Asthmatic AgentsAsthmaBiological ProductsBiomarkersChildChild, PreschoolHealth Services AccessibilityHumansAnti-Asthmatic AgentsBiological ProductsBiomarkers

Identifiers

PMID37652232
PMCPMC10842489
OpenAlexW4386257941

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.